|

Alzheimer's Disease Clinical Trials in Dallas, TX

21 recruiting studies within 50 miles

Phase
Trial Phase Dist.
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease StudiesPhase 3<1 mi
A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's DiseasePhase 3<1 mi
Impact of Intensive Treatment of SBP on Brain Perfusion, Amyloid, and Tau (IPAT Study)Phase 2<1 mi
Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3)—<1 mi
[18F]PI-2620 Phase 3 Histopathological StudyPhase 3<1 mi
A Study to Evaluate the Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia (MK-1167-008)Phase 2<1 mi
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic MutationPhase 2/3<1 mi
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic MutationPhase 2/3<1 mi
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)Phase 3<1 mi
ExAblate Blood-Brain Barrier (BBB) Disruption for the Treatment of Alzheimer's DiseaseN/A<1 mi
Late Onset Alzheimer's Disease—<1 mi
A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's DiseasePhase 3<1 mi
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR VariantPhase 3<1 mi
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)Phase 312 mi
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)Phase 312 mi
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)Phase 313 mi
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)Phase 313 mi
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's DiseasePhase 218 mi
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)Phase 324 mi
Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's TypePhase 331 mi
A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)Phase 231 mi

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.